Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus
Authors:
- 15 October 2011
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 91 (4) , 587-595
Abstract
Cytomegalovirus (CMV) infection and disease are important concerns after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The similarity of hepatitis B virus (HBV) and CMV with regards to their chronic viral persistence and potential reactivation at the time of impaired cellular immunity has raised clinicians’ interest in the occurrence and association between them among patients receiving allo-HSCT; however, only limited data have been obtained from a high seroprevalence region of both CMV and HBV. We monitored 117 adult allo-HSCT patients with both CMV polymerase chain reaction and pp65 antigenemia assay weekly until day 100. In 91.8% of our cases, donors and recipients were both CMV seropositive, and 13.7% of the patients were positive for HBV surface antigen. The incidences of CMV infection and disease were 45.3% and 6.8%, respectively. Grade II–IV acute graft-versus-host disease and anti-thymocyte globulin-containing conditioning regimen were associated with an increased risk of CMV infection in a multivariate analysis (hazard ratio 3.02, 95% CI 1.68–5.42, p < 0.001 and hazard ratio 5.29, 95% CI 2.57–10.8, p < 0.001). No survival disadvantage was found in patients who developed CMV infection (p = 0.699) and CMV disease (p = 0.093). No clinically significant HBV reactivation was found, and the underlying HBV infection in donors or recipients before allo-HSCT did not increase the risk of CMV infection and CMV disease and did not influence survival after allo-HSCT.Keywords
This publication has 33 references indexed in Scilit:
- Management of CMV infections: recommendations from the infectious diseases working party of the EBMTBone Marrow Transplantation, 2004
- Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategiesTransplantation and Cellular Therapy, 2003
- Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantationBlood, 2002
- High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)–Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effects of Primary CMV InfectionThe Journal of Infectious Diseases, 2002
- Successful Modification of a pp65 Antigenemia-Based Early Treatment Strategy for Prevention of Cytomegalovirus Disease in Allogeneic Marrow Transplant RecipientsBlood, 1999
- RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS1Transplantation, 1998
- Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical ApplicationsClinical Microbiology Reviews, 1998
- Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantationBlood, 1995
- Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantationBlood, 1992
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986